Drug Dosing during Intermittent Hemodialysis and Continuous Renal Replacement Therapy: Special Considerations in Pediatric Patients

Pediatric Drugs

Volumn 6, Issue 1, 2004, Pages 45-65

  Veltri, Michael A ^a,b   Neu, Alicia M ^a   Fivush, Barbara A ^a   Parekh, Rulan S ^a   Furth, Susan L ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; ANTIVIRUS AGENT; CEFEPIME; CEFOTAXIME; CEFOTETAN; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLAVULANIC ACID; CREATININE; DIALYSIS FLUID; FAMOTIDINE; FLUCONAZOLE; FLUCYTOSINE; GANCICLOVIR; GENTAMICIN; ITRACONAZOLE; LINEZOLID; POLY(METHYL METHACRYLATE); POLYACRYLONITRILE; POLYAMIDE; POLYSULFONE; TICARCILLIN; UNINDEXED DRUG; VANCOMYCIN;

ACUTE KIDNEY FAILURE; CHILD; CHILDHOOD DISEASE; CHRONIC KIDNEY FAILURE; COMORBIDITY; CONTINUOUS RENAL REPLACEMENT THERAPY; DRUG CLEARANCE; DRUG CROSS REACTIVITY; DRUG DOSE REGIMEN; GENERAL PRACTICE; HEMODIALYSIS; HUMAN; INTENSIVE CARE; KIDNEY TRANSPLANTATION; NEPHROLOGY; PERITONEAL DIALYSIS; PHARMACIST; PRIORITY JOURNAL; REVIEW; TEAMWORK; BLOOD FLOW; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SOLUBILITY; HEMOFILTRATION; KIDNEY CLEARANCE; LIPID SOLUBILITY; MOLECULAR WEIGHT; ULTRAFILTRATION;

ALGORITHMS; CHILD; HUMANS; KIDNEY FAILURE, CHRONIC; METABOLIC CLEARANCE RATE; MOLECULAR WEIGHT; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; PROTEIN BINDING; RENAL DIALYSIS; RENAL REPLACEMENT THERAPY;

EID: 1542287262     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00148581-200406010-00004     Document Type: Review

References (114)

1. Colton CK, Henderson LW, Ford CA, et al. Kinetics of hemodiafiltration (I): in vitro transport characteristics of a hollow-fiber blood ultrafilter. J Lab Clin Med 1975; 85 (3): 355-71
2. Golper TA, Pullium J, Bennett WM. Removal of therapeutic drugs by continuous arteriovenous hemofiltration. Arch Intern Med 1985; 145: 1651-2
3. Golper TA, Wedel SK, Kaplan AA, et al. Drug removal during continuous arteriovenous hemofiltration: theory and clinical observations. Int J Artif Organs 1985; 8: 307-12
4. Levin DL, Morriss FC, editors. Essentials of pediatric intensive care: pharmacokinetics in patients on extracorporeal circuits. 2nd ed. New York (NY): Churchill Livingstone Inc., 1997
5. Joy MS, Matzke GR, Armstrong DK, et al. A primer on continuous renal replacement therapy for critically ill patients. Ann Pharmacother 1998; 32 (3): 362-75
6. Reetze-Bonorden P, Bohler J, Keller E. Drug dosage in patients during continuous renal replacement therapy: pharmacokinetic and therapeutic considerations. Clin Pharmacokinet 1993; 24 (5): 362-79
7. Golper TA. Drug removal during continuous hemofiltration or hemodialysis. Contrib Nephrol 1991; 93: 110-6
8. Davies JG, Kingswood JC, Sharpstone R, et al. Drug removal in continuous haemofiltration and haemodialysis. Br J Hosp Med 1995; 54 (10): 524-8
9. Manns M, Sigler MH, Teehan BP. Continuous renal replacement therapies: an update. Am J Kidney Dis 1998; 32 (2): 185-207
10. Bohler JDJ, Keller F. Pharmacokinetic principles during continuous renal replacement therapy: drugs and dosage. Kidney Int Suppl 1999; 72: S24-8
11. Bressolle F, Kinowski JM, de la Coussaye JE, et al. Clinical pharmacokinetics during continuous haemofiltration. Clin Pharmacokinet 1994; 26 (6): 457-71
12. Hudson JQ. Drug disposition in patients receiving continuous renal replacement therapies. J Ped Pharm Ther 2001; 6: 15-39
13. Yaffee SJ, Aronda JV, editor. Pediatric pharmacology therapeutic principles in practice. 2nd ed. Philadelphia (PA): WB Saunders Co., 1992
14. Harmon WE. Urea kinetic modeling to prescribe hemodialysis in children. In: Nissenson AR, Fine RN, editors. Dialysis therapy. 3rd ed. Philadelphia (PA): Hanley and Belfus Inc., 2002: 6
15. Buur T, Bradbury MG, Smye SW, et al. Reliability of haemodialysis urea kinetic modelling in children. Pediatr Nephrol 1994; 8 (5): 574-8
16. Leone MR, Jenkins RD, Golper TA, et al. Early experience with continuous arteriovenous hemofiltration in critically ill pediatric patients. Crit Care Med 1986; 14 (12): 1058-63
17. Ronco C, Brendolan A, Bragantini L, et al. Treatment of acute renal failure in newborns by continuous arterio-venous hemofiltration. Kidney Int 1986; 29 (4): 908-15
18. Goldstein SL, Currier H, Graf C, et al. Outcome in children receiving continuous venovenous hemofiltration. Pediatrics 2001; 107 (6): 1309-12
19. Kellum JA, Mehta RL, Angus DC, et al. The first international consensus conference on CRRT. Kidney Int 2002; 62: 1855-63
20. Bunchman TE, Donckerwolcke RA. Continuous arterial-venous diahemofiltration and continuous veno-venous diahemofiltration in infants and children. Pediatr Nephrol 1994; 8 (1): 96-102
21. Bunchman TE, Maxvold NJ, Kershaw DB, et al. Continuous venovenous hemodiafiltration in infants and children. Am J Kidney Dis 1995; 25 (1): 17-21
22. Rowland M, Tozer TN. Clinical pharmacokinetics: concepts and applications. 3rd ed. Philadelphia (PA): Lea and Febiger, 1995
23. Mueller BA, Scarim SK, Macias WL. Comparison of imipenem pharmacokinetics in patients with acute or chronic renal failure treated with continuous hemofiltration. Am J Kidney Dis 1993; 21 (2): 172-9
24. Aronoff GR, Berns JS, Brier ME, et al. Drug prescribing in renal failure. 4th ed. Philadelphia (PA): American College of Physicians, 1999
25. Hardman JG, editor. Goodman and Gilman's the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill Health Professions Divisions, 2001
26. Lindsay CA, Bawdon R, Quigley R. Clearance of ticarcillin-clavulanic acid by continuous venovenous hemofiltration in three critically ill children, two with and without concomitant extracorporeal membrane oxygenation. Pharmacotherapy 1996; 16: 458-62
27. DeSoi CA, Sahm DF, Umans JG. Vancomycin elimination during high-flux hemodialysis: kinetic model and comparison of four membranes. Am J Kidney Dis 1992; 20 (4): 354-60
28. Center for Disease Control, Division of Healthcare Quality Promotion [online]. Available from URL: www.cdc.gov/ncidod/hip/dialysis97.pdf [Accessed 2002 Aug 6]
29. Matzke GR, Frye RF, Joy MS, et al. Determinants of ceftriaxone clearance by continuous venovenous hemofiltration and hemodialysis. Pharmacotherapy 2000; 20 (6): 635-43
30. Rumpf KW, Rieger J, Ansorg R, et al. Binding of antibiotics by dialysis membranes and its clinical relevance. Proc Eur Dial Transplant Assoc 1977; 14: 607-9
31. Kraft D, Lode H. Elimination of ampicillin and gentamicin by hemofiltration. Klin Wochenschr 1979; 57: 195-6
32. Gambro Products. Prisma [online]. Available from URL: http://usa-gambro.com/ products/prisma-disposables-filter-data.htm [Accessed 2002 Apr 6]
33. Bunchman TE, Maxvold NJ, Barnett J, et al. Pediatric hemofiltration: normocarb dialysate solution with citrate anticoagulation. Pediatr Nephrol 2002; 17: 150-4
34. US Renal Data System. USRDS 2001 Annual Data Report: atlas of ESRD in the US. Bethesda (MD): National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2001
35. Cytovene®, ganciclovir: product information. Nuttley (NJ): Roche Laboratories Inc., 1998
36. Siberry I. The Harriet Lane handbook. 15th ed. St Louis (MO): Mosby, 2000
37. Taketomo H, Kraus D. Pediatric dosage handbook. 7th ed. Hudson (OH): Lexi-Comp Inc., 2000
38. Micromedex healthcare series. Vol. 111. Greenwood Village (CO): Micromedex, 2002
39. Armstrong DK, Hidalgo HA, Eldadah M. Vancomycin and tobramycin clearance in an infant during continuous hemofiltration. Ann Pharmacother 1993; 27 (2): 224-7
40. Shah M, Quigley R. Rapid removal of vancomycin by continuous veno-venous hemofiltration. Pediatr Nephrol 2000; 14: 912-5
41. Lau AH, John E. Elimination of vancomycin by continuous arteriovenous hemofiltration. Child Nephrol Urol 1988-89; 9: 232-5
42. Matzke GR, Frye RF, Joy MS, et al. Determinants of ceftazidime clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis. Antimicrob Agents Chemother 2000; 44: 1639-44
43. Reed MD, Yamashita TS, Knupp CK, et al. Pharmacokinetics of intravenously and intramuscularly administered cefepime in infants and children. Antimicrobial Agents Chemother 1997 Aug; 41 (88): 1783-7
44. Blumer JL, Reed MD, Knupp C. Review of the pharmacokinetics of cefepime in children. Pediatr Infect Dis J 2001; 20 (3): 337-42
45. Allaouchiche B, Breilh D, Jaumain H, et al. Pharmacokinetics of cefepime during continuous venovenous hemodiafiltration. Antimicrob Agents Chemother 1997 Nov; 41 (11): 2424-7
46. Budavari ES. The Merck index. 12th ed. Whitehouse Station (NJ): The Merck Research Laboratories, 1996
47. Malone RS, Fish DN, Abraham E, et al. Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother 2001; 45 (11): 3148-55
48. Bugge JF. Pharmacokinetics and drug dosing adjustments during CVVH or CVVHD in critically ill patients. Acta Anaesthesiol Scand 2001; 45: 929-34
49. Murray O. Physician desk reference. Montvale (NJ): Medical Economics Company, 2001
50. Boulieu R, Basfien O, Gaillard S, et al. Pharmacokinetics of acyclovir in patients undergoing continuous venovenous hemodialysis. Ther Drug Monit 1997; 19 (6): 701-4
51. Leikin JB, Shicker L, Orlowski J, et al. Hemodialysis removal of acyclovir. Vet Hum Toxicol 1995; 37 (3): 233-4
52. Armendariz E, Chelluri L, Ptachcinski R. Pharmacokinetics of amikacin during continuous veno-venous hemofiltration. Crit Care Med 1990; 18 (6): 675-6
53. Cleary TG, Pickering LK, Kramer WG, et al. Amikacin pharmacokinetics in pediatric patients with malignancy. Antimicrob Agents Chemother 1979; 16 (6): 829-32
54. Kihara M, Ikeda Y, Takagi N, et al. Pharmacokinetics of single-dose intravenous amikacin in critically ill patients undergoing slow hemodialysis. Intensive Care Med 1995; 21 (4): 348-51
55. Kinowski JM, de la Coussaye JE, Bressolle F, et al. Multiple-dose pharmacokinetics of amikacin and ceftazidime in critically ill patients with septic multiple-organ failure during intermittent hemofiltration. Antimicrob Agents Chemother 1993; 37 (3): 464-73
56. Robert R, Rochard E, Malin F, et al. Amikacin pharmacokinetics during continuous veno-venous hemofiltration. Crit Care Med 1991; 19 (4): 588-9
57. Nahata MC, Vashi VI, Swanson RN, et al. Pharmacokinetics of ampicillin and sulbactam in pediatric patients. Antimicrob Agents Chemother 1999; 43 (5): 1225-9
58. Andrassy K. Pharmacokinetics of cefotaxime in dialysis patients. Diagn Microbiol Infect Dis 1995; 22 (1-2): 85-7
59. Ward A, Richards DM. Cefotetan: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 1985; 30 (5): 382-426
60. Buchanan N, Mithal Y, Witcomb M. Cefoxitin: intravenous pharmacokinetics and intramuscular bioavailability in kwashiorkor. Br J Clin Pharmacol 1980; 9 (6): 623-7
61. Feldman WE, Moffitt S, Sprow N. Clinical and pharmacokinetic evaluation of parental cefoxitin in infants and children. Antimicrob Agents Chemother 1980; 17 (4): 669-74
62. Regazzi MB, Chirico G, Cristiani D, et al. Cefoxitin in newborn infants: a clinical and pharmacokinetic study. Eur J Clin Pharmacol 1983; 25 (4): 507-9
63. Joos B, Schmidli M, Keusch G. Pharmacokinetics of antimicrobial agents in anuric patients during continuous venovenous haemofiltration. Nephrol Dial Transplant 1996; 11: 1582-5
64. Davies SP, Lacey LF, Kox WJ, et al. Pharmacokinetics of cefuroxime and ceftazidime in patients with acute renal failure treated by continuous arteriovenous haemodialysis. Nephrol Dial Transplant 1991; 6 (12): 971-6
65. Sato T, Okamoto K, Kitaura M, et al. The pharmacokinetics of ceftazidime during hemodiafiltration in critically ill patients. Artif Organs 1999; 23 (2): 143-5
66. Begue P, Michel B, Chasalette JP, et al. Multicenter clinical study and pharmacokinetics of ceftazidime in children and newborn infants. Pathol Biol (Paris) 1986; 34 (5): 525-9
67. Del Rio M, McCracken Jr GH, Nelson JD, et al. Pharmacokinetics and cerebrospinal fluid bactericidal activity of ceftriaxone in the treatment of pediatric patients with bacterial meningitis. Antimicrob Agents Chemother 1982; 22 (4): 622-7
68. Kroh UF, Lennartz H, Edwards DJ, et al. Pharmacokinetics of ceftriaxone in patients undergoing continuous veno-venous hemofiltration. J Clin Pharmacol 1996; 36 (12): 1114-9
69. Schaad UB, Stoeckel K. Single-dose pharmacokinetics of ceftriaxone in infants and young children. Antimicrob Agents Chemother 1982; 21 (2): 248-53
70. Lares-Asseff I, Lugo-Goytia G, Perez-Guille MG, et al. Cefuroxime bayesian pharmacokinetics in severely ill septic children. Rev Invest Clin 1998; 50 (4): 311-6
71. Weiss LG, Cars O, Danielson BG, et al. Pharmacokinetics of intravenous cefuroxime during intermittent and continuous arteriovenous hemofiltration. Clin Nephrol 1988; 30 (5): 282-6
72. Saima S, Echizen H, Yoshimoto K, et al. Hemofiltrability of H2-receptor antagonist, famotidine, in renal failure patients. J Clin Pharmacol 1990; 30 (2): 159-62
73. Scholz J, Schulz M, Steinfath M, et al. Fluconazole is removed by continuous venovenous hemofiltration in a liver transplant patient. J Mol Med 1995; 73 (3): 145-7
74. Valtonen M, Tiula E, Neuvonen PJ. Effect of continuous venovenous haemofiltration and haemodiafiltration on the elimination of fluconazole in patients with acute renal failure. J Antimicrob Chemother 1997; 40 (5): 695-700
75. Wolter K, Marggraf G, Dermoumi H, et al. Elimination of fluconazole during continuous veno-venous haemodialysis (CVVHD) in a single patient. Eur J Clin Pharmacol 1994; 47 (3): 291-2
76. Brammer KW, Coates PE. Pharmacokinetics of fluconazole in pediatric patients. Eur J Clin Microbiol Infect Dis 1994; 13 (4): 325-9
77. Nicolau DP, Crowe H, Nightingale CH, et al. Effect of continuous arteriovenous hemodiafiltration on the pharmacokinetics of fluconazole. Pharmacotherapy 1994; 14 (4): 502-5
78. Lau AH, Kronfol NO. Elimination of flucytosine by continuous hemofiltration. Am J Nephrol 1995; 15 (4): 327-31
79. Gando S, Kameue T, Nanzaki S, et al. Pharmacokinetics and clearance of ganciclovir during continuous hemodiafiltration. Crit Care Med 1998; 26 (1): 184-7
80. Hayani KC, Hatzopoulos FK, Frank AL, et al. Pharmacokinetics of once-daily dosing of gentamicin in neonates. J Pediatr 1997; 131 (1 Pt 1): 76-80
81. Postovsky S, Ben Arush MW, Kassis E, et al. Pharmacokinetic analysis of gentamicin thrice and single daily dosage in pediatric cancer patients. Pediatr Hematol Oncol 1997; 14 (6): 547-54
82. Bass KD, Larkin SE, Paap C, et al. Pharmacokinetics of once-daily gentamicin dosing in pediatric patients. J Pediatr Surg 1998; 33 (7): 1104-7
83. Jacobs RF, Kearns GL, Trang JM, et al. Single-dose pharmacokinetics of imipenem in children. J Pediatr 1984; 105: 996-1001
84. Kihara M, Ikeda Y, Shibata K, et al. Pharmacokinetic profiles of intravenous imipenem/cilastatin during slow hemodialysis in critically ill patients. Clin Nephrol 1994; 42 (3): 193-7
85. Konishi K, Suzuki H, Saruta T, et al. Removal of imipenem and cilastatin by hemodialysis in patients with end-stage renal failure. Antimicrob Agents Chemother 1991; 35 (8): 1616-20
86. Reed MD, Kliegman RM, Yamashita TS, et al. Clinical pharmacology of imipenem and cilastatin in premature infants during the first week of life. Antimicrob Agents Chemother 1990; 34 (6): 1172-7
87. Tegeder I, Bremer F, Oelkers R, et al. Pharmacokinetics of imipenem-cilastatin in critically ill patients undergoing continuous venovenous hemofiltration. Antimicrob Agents Chemother 1997; 41 (12): 2640-5
88. Coronel B, Persat F, Dorez D, et al. Itraconazole concentrations during continuous haemodiafiltration. J Antimicrob Chemother 1994; 34 (3): 448-9
89. Kearns GL, Abdel-Rahman S, Blumer JL, et al. Single-dose pharmacokinetics of linezolid in infants and children. Pediatr Infect Dis J 2000; 19: 1178-84
90. Clemett D, Markham A. Linezolid. Drugs 2000; 59 (4): 815-27
91. Blumer JL, Reed M, Kearns GL, et al. Sequential, single-dose pharmacokinetic evaluation of meropenem in hospitalized infants and children. Antimicrob Agents Chemother 1995; 39: 1721-5
92. Giles LJ, Jennings AC, Thomson AH, et al. Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration. Crit Care Med 2000; 28 (3): 632-7
93. Krueger WA, Schroeder TH, Hutchison M, et al. Pharmacokinetics of meropenem in critically ill patients with acute renal failure treated by continuous hemodiafiltration. Antimicrob Agents Chemother 1998; 42 (9): 2421-4
94. Meyer MM, Munar MY, Kohlhepp SJ, et al. Meropenem pharmacokinetics in a patient with multiorgan failure from meningococcemia undergoing continuous venovenous hemodiafiltration. Am J Kidney Dis 1999; 33 (4): 790-5
95. Tegeder I, Neumann F, Bremer F, et al. Pharmacokinetics of meropenem in critically ill patients with acute renal failure undergoing continuous venovenous hemofiltration. Clin Pharmacol Ther 1999; 65 (1): 50-7
96. Thalhammer F, Schenk P, Burgmann H, et al. Single-dose pharmacokinetics of meropenem during continuous venovenous hemofiltration. Antimicrob Agents Chemother 1998; 42 (9): 2417-20
97. Valtonen M, Tiula E, Backman JT, et al. Elimination of meropenem during continuous veno-venous haemofiltration and haemodiafiltration in patients with acute renal failure. J Antimicrob Chemother 2000; 45 (5): 701-4
98. Ververs TF, van Dijk A, Vinks SA, et al. Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration. Crit Care Med 2000; 28 (10): 3412-6
99. Kearns GL, van de Anker J, Reed MD, et al. Pharmacokinetics of metoclopramide in neonates. J Clin Pharmacol 1998; 38: 122-8
100. Lares-Asseff I, Cravioto J, Santiago P, et al. A new dosing regimen for metronidazole in malnourished children. Scand J Infect Dis 1993; 25 (1): 115-21
101. Wilson CB, Koup J, Opheim KE, et al. Piperacillin pharmacokinetics in pediatric patients. Antimicrob Agents Chemother 1982; 22: 442-7
102. Capellier G, Cornette C, Boillot A, et al. Removal of piperacillin in critically ill patients undergoing continuous venovenous hemofiltration. Crit Care Med 1998; 26 (1): 88-91
103. Francke EL, Appel GB, Neu HC. Pharmacokinetics of intravenous piperacillin in patients undergoing chronic hemodialysis. Antimicrob Agents Chemother 1979; 16 (6): 788-91
104. Keller E, Bohler J, Busse-Grawitz A, et al. Single dose kinetics of piperacillin during continuous arteriovenous hemodialysis in intensive care patients. Clin Nephrol 1995; 43 Suppl. 1: S20-3
105. Reed MD, Goldfarb J, Yamashita TS, et al. Single-dose pharmacokinetics of piperacillin and tazobactam in infants and children. Antimicrob Agents Chemother 1994; 38: 2817-26
106. Van der Werf TS, Mulder PO, Zijlstra JG, et al. Pharmacokinetics of piperacillin and tazobactam in critically ill patients with renal failure, treated with continuous veno-venous hemofiltration (CVVH). Intensive Care Med 1997; 23 (8): 873-7
107. Gladziwa U, Krishna DR, Klotz U, et al. Pharmacokinetics of ranitidine in patients undergoing haemofiltration. Eur J Clin Pharmacol 1988; 35 (4): 427-30
108. Lugo RA, Cash J, Sweeley J, et al. Pharmacokinetics and pharmacodynamics of ranitidine in critically ill children. Crit Care Med 2001; 29: 759-64
109. Reed MD, Yamashita TS, Blumer JL. Pharmacokinetic-based ticarcillin/clavulanic acid dose recommendations for infants and children. J Clin Pharmacol 1995; 35: 658-65
110. Scott MK, Macias WL, Kraus MA, et al. Effects of dialysis membrane on intradialytic vancomycin administration. Pharmacotherapy 1997; 17 (2): 256-62
111. Torras J, Cao C, Rivas MC, et al. Pharmacokinetics of vancomycin in patients undergoing hemodialysis with polyacrylonitrile. Clin Nephrol 1991; 36 (1): 35-41
112. Barth RH, DeVincenzo N. Use of vancomycin in high-flux hemodialysis: experience with 130 courses of therapy. Kidney Int 1996; 50 (3): 929-36
113. Brunet S, Leblanc M, Geadah D, et al. Diffusive and convective solute clearances during continuous renal replacement therapy at various dialysate and ultrafiltration flow rates. Am J Kidney Dis 1999; 34 (3): 486-92
114. Brophy PD, Maxvold N, Bunchman TE. CAVH/CVVH in pediatric patients. In: Nissenson AR, Fine RD, editors. Dialysis therapy. 3rd ed. Philadelphia (PA): Hanley and Belfus Inc., 2002